The Experts below are selected from a list of 273 Experts worldwide ranked by ideXlab platform

Dean K. Naritoku - One of the best experts on this subject based on the ideXlab platform.

  • Gabapentin for the Treatment of Hemifacial Spasm
    Clinical Neuropharmacology, 1996
    Co-Authors: Jayantibhai Patel, Dean K. Naritoku
    Abstract:

    Summary: Pharmacologic therapy for Hemifacial Spasm is often limited by the paucity of effective medications and problems with side effects. Gabapentin is a novel antiepileptic drug that is generally well tolerated. Its anticonvulsant effect is independent of y-aminobenzoic acid (GABA) receptor mechanisms. We report a patient with Hemifacial Spasm who responded well to gabapentin therapy. Gabapentin may be a useful alternative medical therapy to currently used drugs.

E. Natale - One of the best experts on this subject based on the ideXlab platform.

  • Gabapentin in the treatment of Hemifacial Spasm
    Acta Neurologica Scandinavica, 2001
    Co-Authors: Ornella Daniele, G. Caravaglios, C. Marchini, L. Mucchiut, P. Capus, E. Natale
    Abstract:

    Objectives– To evaluate the efficacy of gabapentin in the treatment of Hemifacial Spasm. Material and methods– Twenty-three patients with Hemifacial Spasm not suitable for surgery or therapy with botulinum toxin were treated with gabapentin. The main efficacy parameter was the percentage of Spasm reduction. Results– A clinically significant reduction of Spasms was obtained by 16 patients. Conclusion– Gabapentin was effective and safe in reducing Hemifacial Spasm in 16 out 23 (69.6%) patients.

Jayantibhai Patel - One of the best experts on this subject based on the ideXlab platform.

  • Gabapentin for the Treatment of Hemifacial Spasm
    Clinical Neuropharmacology, 1996
    Co-Authors: Jayantibhai Patel, Dean K. Naritoku
    Abstract:

    Summary: Pharmacologic therapy for Hemifacial Spasm is often limited by the paucity of effective medications and problems with side effects. Gabapentin is a novel antiepileptic drug that is generally well tolerated. Its anticonvulsant effect is independent of y-aminobenzoic acid (GABA) receptor mechanisms. We report a patient with Hemifacial Spasm who responded well to gabapentin therapy. Gabapentin may be a useful alternative medical therapy to currently used drugs.

Ornella Daniele - One of the best experts on this subject based on the ideXlab platform.

  • Gabapentin in the treatment of Hemifacial Spasm
    Acta Neurologica Scandinavica, 2001
    Co-Authors: Ornella Daniele, G. Caravaglios, C. Marchini, L. Mucchiut, P. Capus, E. Natale
    Abstract:

    Objectives– To evaluate the efficacy of gabapentin in the treatment of Hemifacial Spasm. Material and methods– Twenty-three patients with Hemifacial Spasm not suitable for surgery or therapy with botulinum toxin were treated with gabapentin. The main efficacy parameter was the percentage of Spasm reduction. Results– A clinically significant reduction of Spasms was obtained by 16 patients. Conclusion– Gabapentin was effective and safe in reducing Hemifacial Spasm in 16 out 23 (69.6%) patients.

Reyes E - One of the best experts on this subject based on the ideXlab platform.

  • Botulinum toxin-A for the treatment of Hemifacial Spasm.
    Archives of medical research, 1995
    Co-Authors: Carlos Cuevas, Ignacio Madrazo, Magallón E, Carlos Zamorano, G. Neri, Reyes E
    Abstract:

    Management of Hemifacial Spasm can actually be done medically, surgically and with Botulinum-A Toxin. The Botulinum-A Toxin treatment locally injected into the involved facial muscles offers a useful alternative to medical and surgical therapy. The objective of this study was to evaluate the efficacy of Botulinum-A Toxin for the treatment of Hemifacial Spasm in those subjects for whom the presently available medical therapy is inadequate. A total of 28 individuals were enrolled in the clinical study. Patients were evaluated using the Fahn's blepharoSpasm rating and disability scales. Efficacy was assessed by evaluating changes from the baseline in eyelid Spasm intensity, brow Spasm intensity, eyelid force and facial Spasm intensity. All 28 subjects with Hemifacial Spasm showed clinical improvement in relation to this baseline, which was statistically significant. The mean decrease from baseline at their follow-up examination was statistically significant for all subjects and for all measurements: eyelid Spasm changed from 2.3 to 0.3 (p = 0.0001); brow Spasm from 1.9 to 0.1 (p = 0.0001); facial Spasm from 2.3 to 0.1 (p = 0.0001) and eyelid force from 0.9 to -0.1 (p = 0.0020). We concluded that Botulinum-A Toxin provides a significant therapeutic benefit to patients with Hemifacial Spasm, without the risk of disabling side effects.